This review highlights the underrecognized risk of HFpEF in cancer patients and survivors, emphasizing the need for comprehensive cardiovascular monitoring beyond just left ventricular ejection fraction.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jorge et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: